% | $
Quotes you view appear here for quick access.

MannKind Corp. Message Board

  • redhaw_2000 redhaw_2000 Feb 15, 2014 8:39 PM Flag

    Dr. Jay Skyler thinks Mannkind's Afrezza will be approved.

    Jay S. Skyler, M.D., M.A.C.P., is a Professor of Medicine, Pediatrics and Psychology at the University of Miami Miller School of Medicine and Deputy Director for Clinical Research and Academic Programs at the Diabetes Research Institute.

    He also is an Adjunct Professor of Pediatrics at the Barbara Davis Center for Childhood Diabetes, University of Colorado at Denver. Dr. Skyler's career in diabetes spans over four decades, where his research interests have concentrated in clinical aspects of diabetes, particularly improving the care of Type 1 diabetes through meticulous glycemic control, psychosocial and behavioral support, and immune intervention.

    He was Study Chairman for the nationwide multi-center Diabetes Prevention Trial for Type 1 diabetes (DPT-1) and now serves as Study Chairman of its successor, the NIH-sponsored Type 1 Diabetes TrialNet, an international network conducting clinical trials to interdict Type 1 diabetes.

    He is a past President of the American Diabetes Association, the International Diabetes Immunotherapy Group, and the Southern Society for Clinical Investigation, and was a Vice-President of the International Diabetes Federation. He served as a member of the Endocrinology, Diabetes, and Metabolism Subspecialty Examining Board of the American Board of Internal Medicine, as Chairman of the Council of Subspecialty Societies of the American College of Physicians (ACP) and a member of the ACP Board of Regents. A frequent national and international lecturer, Dr. Skyler has been an author, editor and co-editor of numerous books, monographs, chapters and articles. He was founding Editor-in-Chief of Diabetes Care.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.609-0.006(-1.02%)Sep 28 4:00 PMEDT